Cargando…

Nano-liposomal zein hydrolysate for improved apoptotic activity and therapeutic index in lung cancer treatment

Lung cancer is one of the most common cancers in the world with a high mortality rate. Zein is a protein compound whose protein isolate is not useful and whose protein hydrolysis produces biological activity. By encapsulating this bioactive compound inside the nanoparticles (NPs), it causes itself t...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazloum-Ravasan, Sahand, Mohammadi, Maryam, Hiagh, Elaheh Madadi, Ebrahimi, Alireza, Hong, Joo-Hyun, Hamishehkar, Hamed, Kim, Ki Hyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979517/
https://www.ncbi.nlm.nih.gov/pubmed/35363101
http://dx.doi.org/10.1080/10717544.2022.2057618
_version_ 1784681192948236288
author Mazloum-Ravasan, Sahand
Mohammadi, Maryam
Hiagh, Elaheh Madadi
Ebrahimi, Alireza
Hong, Joo-Hyun
Hamishehkar, Hamed
Kim, Ki Hyun
author_facet Mazloum-Ravasan, Sahand
Mohammadi, Maryam
Hiagh, Elaheh Madadi
Ebrahimi, Alireza
Hong, Joo-Hyun
Hamishehkar, Hamed
Kim, Ki Hyun
author_sort Mazloum-Ravasan, Sahand
collection PubMed
description Lung cancer is one of the most common cancers in the world with a high mortality rate. Zein is a protein compound whose protein isolate is not useful and whose protein hydrolysis produces biological activity. By encapsulating this bioactive compound inside the nanoparticles (NPs), it causes itself to reach the tumor site and destroy it rapidly. In this study, the effects of zein hydrolysate (ZH) and nano-liposomal ZH (N-ZH) were investigated on the human A549 cell line. Western blotting and cell cycle analyses showed that ZH and N-ZH caused cytotoxicity. They induced apoptosis via cell cycle arrest at the G0 phase, as well as significant increases in pro-apoptotic genes, such as Bax, caspase-3, -8, -9, and p53, accompanied with significant decreases in the anti-apoptotic marker Bcl-2. Based on the results, the cytotoxic and anticancer effects of N-ZH were higher than those of free ZH. In conclusion, liposomes improved the performance of ZH and dramatically reduced the IC(50) value of ZH. These findings provided the experimental evidence that N-ZH with favorable anticancer activity can be used as a therapeutic agent and strategy for lung cancer treatment in future clinical trials.
format Online
Article
Text
id pubmed-8979517
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-89795172022-04-05 Nano-liposomal zein hydrolysate for improved apoptotic activity and therapeutic index in lung cancer treatment Mazloum-Ravasan, Sahand Mohammadi, Maryam Hiagh, Elaheh Madadi Ebrahimi, Alireza Hong, Joo-Hyun Hamishehkar, Hamed Kim, Ki Hyun Drug Deliv Research Article Lung cancer is one of the most common cancers in the world with a high mortality rate. Zein is a protein compound whose protein isolate is not useful and whose protein hydrolysis produces biological activity. By encapsulating this bioactive compound inside the nanoparticles (NPs), it causes itself to reach the tumor site and destroy it rapidly. In this study, the effects of zein hydrolysate (ZH) and nano-liposomal ZH (N-ZH) were investigated on the human A549 cell line. Western blotting and cell cycle analyses showed that ZH and N-ZH caused cytotoxicity. They induced apoptosis via cell cycle arrest at the G0 phase, as well as significant increases in pro-apoptotic genes, such as Bax, caspase-3, -8, -9, and p53, accompanied with significant decreases in the anti-apoptotic marker Bcl-2. Based on the results, the cytotoxic and anticancer effects of N-ZH were higher than those of free ZH. In conclusion, liposomes improved the performance of ZH and dramatically reduced the IC(50) value of ZH. These findings provided the experimental evidence that N-ZH with favorable anticancer activity can be used as a therapeutic agent and strategy for lung cancer treatment in future clinical trials. Taylor & Francis 2022-04-01 /pmc/articles/PMC8979517/ /pubmed/35363101 http://dx.doi.org/10.1080/10717544.2022.2057618 Text en © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Mazloum-Ravasan, Sahand
Mohammadi, Maryam
Hiagh, Elaheh Madadi
Ebrahimi, Alireza
Hong, Joo-Hyun
Hamishehkar, Hamed
Kim, Ki Hyun
Nano-liposomal zein hydrolysate for improved apoptotic activity and therapeutic index in lung cancer treatment
title Nano-liposomal zein hydrolysate for improved apoptotic activity and therapeutic index in lung cancer treatment
title_full Nano-liposomal zein hydrolysate for improved apoptotic activity and therapeutic index in lung cancer treatment
title_fullStr Nano-liposomal zein hydrolysate for improved apoptotic activity and therapeutic index in lung cancer treatment
title_full_unstemmed Nano-liposomal zein hydrolysate for improved apoptotic activity and therapeutic index in lung cancer treatment
title_short Nano-liposomal zein hydrolysate for improved apoptotic activity and therapeutic index in lung cancer treatment
title_sort nano-liposomal zein hydrolysate for improved apoptotic activity and therapeutic index in lung cancer treatment
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979517/
https://www.ncbi.nlm.nih.gov/pubmed/35363101
http://dx.doi.org/10.1080/10717544.2022.2057618
work_keys_str_mv AT mazloumravasansahand nanoliposomalzeinhydrolysateforimprovedapoptoticactivityandtherapeuticindexinlungcancertreatment
AT mohammadimaryam nanoliposomalzeinhydrolysateforimprovedapoptoticactivityandtherapeuticindexinlungcancertreatment
AT hiaghelahehmadadi nanoliposomalzeinhydrolysateforimprovedapoptoticactivityandtherapeuticindexinlungcancertreatment
AT ebrahimialireza nanoliposomalzeinhydrolysateforimprovedapoptoticactivityandtherapeuticindexinlungcancertreatment
AT hongjoohyun nanoliposomalzeinhydrolysateforimprovedapoptoticactivityandtherapeuticindexinlungcancertreatment
AT hamishehkarhamed nanoliposomalzeinhydrolysateforimprovedapoptoticactivityandtherapeuticindexinlungcancertreatment
AT kimkihyun nanoliposomalzeinhydrolysateforimprovedapoptoticactivityandtherapeuticindexinlungcancertreatment